LM103
Phase 2Biologic
LM103 is one of 58 biologic programs targeting Non-Small Cell Lung Cancer. It is currently in Phase 2.
2
Indications
6
Total Trials
5
Active Trials
57
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
1639 competitors in Non-Small Cell Lung Cancer
#DrugCompanyPhaseTrials
1Vizimpro
PfizerPreclinical
Immunotherapy
Bristol-Myers SquibbPreclinical
LM103
SSuzhou BlueHorse Therapeutics Co., Ltd.
Phase 2
Remeron
OOrganon and Co
Preclinical
Tyrosine Kinase Inhibitor
PfizerPreclinical
Aqupla
Jiangsu Simcere Pharmaceutical Co., Ltd.Preclinical
Treatment
GSKPreclinical
Vidaza
Bristol-Myers SquibbPreclinical
REGN2810
RegeneronPreclinical
Huaier Granule
QQidong Gaitianli Medicines Co., Ltd
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Advanced Solid Tumors3 trials
Non-Small Cell Lung Cancer1 trial
Advanced Solid Tumours1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for LM103. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details